Outcomes, Safety and Tolerability of Sacubitril-Valsartan over 3 years of Follow-up in Canadian Practice: Insights from the PARTHENON Registry
{{output}}
Background: Experience with sacubitril-valsartan in real-world patients with heart failure and reduced ejection fraction (HFrEF) is congruent with findings from clinical trials. Detailed assessment of safety and clinical outcomes... ...
